Home / Therapeutic Area / Dermatology Therapeutics Drug Development Pipeline Review, 2016

Dermatology Therapeutics Drug Development Pipeline Review, 2016

Published: Apr 2017 | No Of Pages: 432 | Published By: GBI Research

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.

Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.

The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

Which companies are the most active within the pipeline for dermatology?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 13
Introduction 15
GBI Research Report Coverage 15
Acne Vulgaris Overview 15
Psoriasis Overview 15
Atopic Dermatitis Overview 15
Therapeutics Development 16
Acne Vulgaris 16
Psoriasis 18
Atopic Dermatitis 20
Therapeutics under Development by Companies 22
Acne Vulgaris 22
Psoriasis 24
Atopic Dermatitis 31
Therapeutics under Investigation by Universities/Institutes 34
Acne Vulgaris 34
Psoriasis 35
Atopic Dermatitis 36
Pipeline Products Glance 37
Acne Vulgaris 37
Psoriasis 40
Atopic Dermatitis 44
Products under Development by Companies 47
Acne Vulgaris 47
Psoriasis 49
Atopic Dermatitis 58
Products under Investigation by Universities/Institutes 62
Acne Vulgaris 62
Psoriasis 62
Atopic Dermatitis 63
Companies Involved in Therapeutics Development 64
Acne Vulgaris 64
Psoriasis 95
Atopic Dermatitis 245
Therapeutics Assessment 323
Acne Vulgaris 323
Psoriasis 335
Atopic Dermatitis 363
Dormant Projects 377
Acne Vulgaris 377
Psoriasis 380
Atopic Dermatitis 389
Discontinued Products 392
Acne Vulgaris 392
Psoriasis 392
Atopic Dermatitis 395
Product Development Milestones 396
Acne Vulgaris 396
Psoriasis 408
Atopic Dermatitis 420

Appendix 431
Methodology 431
Coverage 431
Secondary Research 431
Primary Research 431
Expert Panel Validation 431
Contact Us 431
Disclaimer 432

Number of Products under Development for Acne Vulgaris, 16
Number of Products under Development for Acne Vulgaris – Comparative Analysis, 17
Number of Products under Development for Psoriasis, 18
Number of Products under Development for Psoriasis – Comparative Analysis, 19
Number of Products under Development for Atopic Dermatitis, 20
Number of Products under Development for Atopic Dermatitis – Comparative Analysis, 21
Number of Products under Development by Companies 22
Number of Products under Development by Companies 25
Number of Products under Development by Companies 31
Number of Products under Investigation by Universities/Institutes, 34
Number of Products under Investigation by Universities/Institutes, 34
Number of Products under Investigation by Universities/Institutes, 35
Number of Products under Investigation by Universities/Institutes, 36
Comparative Analysis by Late Stage Development, 37
Comparative Analysis by Clinical Stage Development, 38
Comparative Analysis by Early Stage Development, 39
Comparative Analysis by Late Stage Development, 40
Comparative Analysis by Clinical Stage Development, 41
Comparative Analysis by Early Stage Development, 42
Comparative Analysis by Unknown Stage Development, 43
Comparative Analysis by Late Stage Development, 44
Comparative Analysis by Clinical Stage Development, 45
Comparative Analysis by Early Stage Development, 46
Products under Development by Companies 47
Products under Development by Companies 49
Products under Development by Companies, 58
Products under Investigation by Universities/Institutes, 62
Products under Investigation by Universities/Institutes, 62
Products under Investigation by Universities/Institutes, 63
Acne Vulgaris – Pipeline by 3SBio Inc, 64
Acne Vulgaris – Pipeline by Allergan Plc, 64
Acne Vulgaris – Pipeline by Almirall SA, 65
Acne Vulgaris – Pipeline by Antibiotx ApS, 65
Acne Vulgaris – Pipeline by Biomar Microbial Technologies, 66
Acne Vulgaris – Pipeline by BioPharmX Inc, 66
Acne Vulgaris – Pipeline by Braintree Laboratories Inc, 67
Acne Vulgaris – Pipeline by Brickell Biotech Inc, 67
Acne Vulgaris – Pipeline by Cell Medica Ltd, 68
Acne Vulgaris – Pipeline by Cellceutix Corp, 68
Acne Vulgaris – Pipeline by Celtaxsys Inc, 69
Acne Vulgaris – Pipeline by Common Pharma Inc, 69
Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, 70
Acne Vulgaris – Pipeline by DermaXon LLC, 70
Acne Vulgaris – Pipeline by Dermira Inc, 71
Acne Vulgaris – Pipeline by ELORAC Inc, 71
Acne Vulgaris – Pipeline by Ensol Biosciences Inc, 72
Acne Vulgaris – Pipeline by Foamix Pharmaceuticals Ltd, 72
Acne Vulgaris – Pipeline by Galderma SA, 73
Acne Vulgaris – Pipeline by GlaxoSmithKline Plc, 73
Acne Vulgaris – Pipeline by Helix BioMedix Inc, 74
Acne Vulgaris – Pipeline by Hovione FarmaCiencia SA, 74
Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Ltd, 75
Acne Vulgaris – Pipeline by LEO Pharma A/S, 76
Acne Vulgaris – Pipeline by Novabiotics Ltd, 77
Acne Vulgaris – Pipeline by Novan Inc, 78
Acne Vulgaris – Pipeline by Paratek Pharmaceuticals Inc, 79
Acne Vulgaris – Pipeline by Pfizer Inc, 80
Acne Vulgaris – Pipeline by Phosphagenics Ltd, 81
Acne Vulgaris – Pipeline by Photocure ASA, 82
Acne Vulgaris – Pipeline by Promius Pharma LLC, 83
Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, 84
Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 85
Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd, 86
Acne Vulgaris – Pipeline by Sun Pharma Advanced Research Company Ltd, 87
Acne Vulgaris – Pipeline by Telesso Technologies Ltd, 88
Acne Vulgaris – Pipeline by Thesan Pharmaceuticals Inc, 89
Acne Vulgaris – Pipeline by Valeant Pharmaceuticals International Inc, 90
Acne Vulgaris – Pipeline by Vectura Group Plc, 91
Acne Vulgaris – Pipeline by Vyome Biosciences Pvt Ltd, 92
Acne Vulgaris – Pipeline by XBiotech Inc, 93
Acne Vulgaris – Pipeline by Xenon Pharmaceuticals Inc, 94
Psoriasis – Pipeline by AbbVie Inc, 95
Psoriasis – Pipeline by Abeome Corp, 96
Psoriasis – Pipeline by AbGenomics International Inc, 97
Psoriasis – Pipeline by Addex Therapeutics Ltd, 98
Psoriasis – Pipeline by Adello Biologics LLC, 99
Psoriasis – Pipeline by Advinus Therapeutics Ltd, 100
Psoriasis – Pipeline by Affibody AB, 101
Psoriasis – Pipeline by Albireo Pharma Inc, 102
Psoriasis – Pipeline by Alfacyte Ltd, 103
Psoriasis – Pipeline by Almirall SA, 104
Psoriasis – Pipeline by Alteogen Inc, 105
Psoriasis – Pipeline by Amgen Inc, 106
Psoriasis – Pipeline by Anacor Pharmaceuticals Inc, 107
Psoriasis – Pipeline by AnaptysBio Inc, 108
Psoriasis – Pipeline by ApoPharma Inc, 109
Psoriasis – Pipeline by Arena Pharmaceuticals Inc, 110
Psoriasis – Pipeline by Argos Therapeutics Inc, 111
Psoriasis – Pipeline by Arrien Pharmaceuticals LLC, 112
Psoriasis – Pipeline by AstraZeneca Plc, 113
Psoriasis – Pipeline by Athenex Inc, 114
Psoriasis – Pipeline by Atlantic Bio Sci LLC, 115
Psoriasis – Pipeline by Aurigene Discovery Technologies Ltd, 116
Psoriasis – Pipeline by Aurinia Pharmaceuticals Inc, 117
Psoriasis – Pipeline by Avexxin AS, 118
Psoriasis – Pipeline by Bayer AG, 119
Psoriasis – Pipeline by Betta Pharmaceuticals Co Ltd, 120
Psoriasis – Pipeline by BioApex sro, 121
Psoriasis – Pipeline by Biocad, 122
Psoriasis – Pipeline by Biocon Ltd, 123
Psoriasis – Pipeline by BioLingus AG, 124
Psoriasis – Pipeline by BioMAS Ltd, 125
Psoriasis – Pipeline by Biomics Biotechnologies Co Ltd, 126
Psoriasis – Pipeline by Bionomics Ltd, 127
Psoriasis – Pipeline by Bionovis SA, 128
Psoriasis – Pipeline by BirchBioMed Inc, 129
Psoriasis – Pipeline by Boehringer Ingelheim GmbH, 130
Psoriasis – Pipeline by Brickell Biotech Inc, 131
Psoriasis – Pipeline by Bristol-Myers Squibb Company, 132
Psoriasis – Pipeline by C4X Discovery Holdings PLC, 133
Psoriasis – Pipeline by CalciMedica Inc, 134
Psoriasis – Pipeline by Can-Fite BioPharma Ltd, 135
Psoriasis – Pipeline by Celgene Corp, 136
Psoriasis – Pipeline by Cell Medica Ltd, 137
Psoriasis – Pipeline by Cellceutix Corp, 138
Psoriasis – Pipeline by ChemoCentryx Inc, 139
Psoriasis – Pipeline by Chipscreen Biosciences Ltd, 140
Psoriasis – Pipeline by ChironWells GmbH, 141
Psoriasis – Pipeline by Coherus BioSciences Inc, 142
Psoriasis – Pipeline by Compugen Ltd, 143
Psoriasis – Pipeline by Convoy Therapeutics Inc, 144
Psoriasis – Pipeline by Creabilis SA, 145
Psoriasis – Pipeline by Crescendo Biologics Ltd, 146
Psoriasis – Pipeline by Curapel Ltd, 147
Psoriasis – Pipeline by Cutanea Life Sciences Inc, 148
Psoriasis – Pipeline by Dermala Inc, 149
Psoriasis – Pipeline by Domainex Ltd, 150
Psoriasis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, 151
Psoriasis – Pipeline by EA Pharma Co Ltd, 152
Psoriasis – Pipeline by Eli Lilly and Company, 153
Psoriasis – Pipeline by ELORAC Inc, 154
Psoriasis – Pipeline by Exicure Inc, 155
Psoriasis – Pipeline by Foamix Pharmaceuticals Ltd, 156
Psoriasis – Pipeline by Forward Pharma A/S, 157
Psoriasis – Pipeline by Gem Pharmaceuticals LLC, 158
Psoriasis – Pipeline by Genentech Inc, 159
Psoriasis – Pipeline by Genor BioPharma Co Ltd, 160
Psoriasis – Pipeline by GlaxoSmithKline Plc, 161
Psoriasis – Pipeline by GlycoMar Ltd, 162
Psoriasis – Pipeline by Grupo Ferrer Internacional SA, 163
Psoriasis – Pipeline by HitGen LTD, 164
Psoriasis – Pipeline by Huabo Biopharm Co Ltd, 165
Psoriasis – Pipeline by Hydra Biosciences Inc, 166
Psoriasis – Pipeline by iCo Therapeutics Inc., 167
Psoriasis – Pipeline by Idera Pharmaceuticals Inc, 168
Psoriasis – Pipeline by Iltoo Pharma, 169
Psoriasis – Pipeline by Immune Pharmaceuticals Inc, 170
Psoriasis – Pipeline by Immune Response BioPharma Inc, 171
Psoriasis – Pipeline by Immungenetics AG, 172
Psoriasis – Pipeline by Innovent Biologics Inc, 173
Psoriasis – Pipeline by Jenrin Discovery Inc, 174
Psoriasis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 175
Psoriasis – Pipeline by Johnson & Johnson, 176
Psoriasis – Pipeline by Kadmon Corp LLC, 177
Psoriasis – Pipeline by KaloBios Pharmaceuticals Inc, 178
Psoriasis – Pipeline by Kang Stem Biotech Co Ltd, 179
Psoriasis – Pipeline by KPI Therapeutics Inc, 180
Psoriasis – Pipeline by Lead Pharma Holding BV, 181
Psoriasis – Pipeline by Lee's Pharmaceutical Holdings Ltd, 182
Psoriasis – Pipeline by LEO Pharma A/S, 183
Psoriasis – Pipeline by Lipidor AB, 184
Psoriasis – Pipeline by Lupin Ltd, 185
Psoriasis – Pipeline by Lycera Corp, 186
Psoriasis – Pipeline by mAbxience SA, 187
Psoriasis – Pipeline by Maruho Co Ltd, 188
Psoriasis – Pipeline by Medestea Research & Production SpA, 189
Psoriasis – Pipeline by MediGene AG, 190
Psoriasis – Pipeline by Merck KGaA, 191
Psoriasis – Pipeline by MetrioPharm AG, 192
Psoriasis – Pipeline by Mitsubishi Tanabe Pharma Corp, 193
Psoriasis – Pipeline by Momenta Pharmaceuticals Inc, 194
Psoriasis – Pipeline by Mycenax Biotech Inc, 195
Psoriasis – Pipeline by NeuClone Pty Ltd, 196
Psoriasis – Pipeline by Nimbus Therapeutics LLC, 197
Psoriasis – Pipeline by NovaLead Pharma Pvt Ltd, 198
Psoriasis – Pipeline by Novan Inc, 199
Psoriasis – Pipeline by Novartis AG, 200
Psoriasis – Pipeline by Nuevolution AB, 201
Psoriasis – Pipeline by Numedii Inc, 202
Psoriasis – Pipeline by Oncobiologics Inc, 203
Psoriasis – Pipeline by OSE Immunotherapeutics, 204
Psoriasis – Pipeline by Panacea Biotec Ltd, 205
Psoriasis – Pipeline by Pfizer Inc, 206
Psoriasis – Pipeline by Pharis Biotec GmbH, 207
Psoriasis – Pipeline by Pharmedartis GmbH, 208
Psoriasis – Pipeline by Pieris Pharmaceuticals Inc, 209
Psoriasis – Pipeline by PinCell srl, 210
Psoriasis – Pipeline by Promius Pharma LLC, 211
Psoriasis – Pipeline by Protalix BioTherapeutics Inc, 212
Psoriasis – Pipeline by Prothena Corp Plc, 213
Psoriasis – Pipeline by Provectus Biopharmaceuticals Inc, 214
Psoriasis – Pipeline by RedHill Biopharma Ltd, 215
Psoriasis – Pipeline by Reliance Life Sciences Pvt Ltd, 216
Psoriasis – Pipeline by Samumed LLC, 217
Psoriasis – Pipeline by Sandoz International GmbH, 218
Psoriasis – Pipeline by Sareum Holdings Plc, 219
Psoriasis – Pipeline by Selvita SA, 220
Psoriasis – Pipeline by Shanghai Celgen Bio-Pharmaceutical Co Ltd, 221
Psoriasis – Pipeline by Shulov Innovative Science Ltd, 222
Psoriasis – Pipeline by Sigmoid Pharma Ltd, 223
Psoriasis – Pipeline by Soligenix Inc, 224
Psoriasis – Pipeline by Spherium Biomed SL, 225
Psoriasis – Pipeline by Stemline Therapeutics Inc, 226
Psoriasis – Pipeline by sterna biologicals Gmbh & Co KG, 227
Psoriasis – Pipeline by Sucampo Pharmaceuticals Inc, 228
Psoriasis – Pipeline by Sun Pharma Advanced Research Company Ltd, 229
Psoriasis – Pipeline by SWITCH Biotech LLC, 230
Psoriasis – Pipeline by Takeda Pharmaceutical Company Ltd, 231
Psoriasis – Pipeline by Tasly Pharmaceutical Group Co Ltd, 232
Psoriasis – Pipeline by Telormedix SA, 233
Psoriasis – Pipeline by Teva Pharmaceutical Industries Ltd, 234
Psoriasis – Pipeline by TheraMAB LLC, 235
Psoriasis – Pipeline by Therapix Biosciences Ltd, 236
Psoriasis – Pipeline by UCB SA, 237
Psoriasis – Pipeline by Valeant Pharmaceuticals International Inc, 238
Psoriasis – Pipeline by Vitae Pharmaceuticals Inc, 239
Psoriasis – Pipeline by Wellstat Therapeutics Corp, 240
Psoriasis – Pipeline by XBiotech Inc, 241
Psoriasis – Pipeline by XenoPort Inc, 242
Psoriasis – Pipeline by Yuhan Corp, 243
Psoriasis – Pipeline by Ziarco Pharma Ltd, 244
Atopic Dermatitis – Pipeline by AbbVie Inc, 245
Atopic Dermatitis – Pipeline by Abeome Corp, 246
Atopic Dermatitis – Pipeline by Accolade Pharmaceuticals LLC, 247
Atopic Dermatitis – Pipeline by Albireo Pharma Inc, 248
Atopic Dermatitis – Pipeline by Almirall SA, 249
Atopic Dermatitis – Pipeline by Amgen Inc, 250
Atopic Dermatitis – Pipeline by Amorepacific Corp, 251
Atopic Dermatitis – Pipeline by Anacor Pharmaceuticals Inc, 252
Atopic Dermatitis – Pipeline by AnaMar AB, 253
Atopic Dermatitis – Pipeline by AnaptysBio Inc, 254
Atopic Dermatitis – Pipeline by AnGes MG Inc, 255
Atopic Dermatitis – Pipeline by Avexxin AS, 256
Atopic Dermatitis – Pipeline by Blueberry Therapeutics Ltd, 257
Atopic Dermatitis – Pipeline by Brickell Biotech Inc, 258
Atopic Dermatitis – Pipeline by Celgene Corp, 259
Atopic Dermatitis – Pipeline by Cell Medica Ltd, 260
Atopic Dermatitis – Pipeline by Cellceutix Corp, 261
Atopic Dermatitis – Pipeline by ChemoCentryx Inc, 262
Atopic Dermatitis – Pipeline by ChironWells GmbH, 263
Atopic Dermatitis – Pipeline by Chugai Pharmaceutical Co Ltd, 264
Atopic Dermatitis – Pipeline by Clevexel Pharma SA, 265
Atopic Dermatitis – Pipeline by Creabilis SA, 266
Atopic Dermatitis – Pipeline by Curapel Ltd, 267
Atopic Dermatitis – Pipeline by Cutanea Life Sciences Inc, 268
Atopic Dermatitis – Pipeline by Dermala Inc, 269
Atopic Dermatitis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, 270
Atopic Dermatitis – Pipeline by Eli Lilly and Company, 271
Atopic Dermatitis – Pipeline by F. Hoffmann-La Roche Ltd, 272
Atopic Dermatitis – Pipeline by Foamix Pharmaceuticals Ltd, 273
Atopic Dermatitis – Pipeline by Fountain Biopharma Inc, 274
Atopic Dermatitis – Pipeline by Galapagos NV, 275
Atopic Dermatitis – Pipeline by GlaxoSmithKline Plc, 276
Atopic Dermatitis – Pipeline by Glenmark Pharmaceuticals Ltd, 277
Atopic Dermatitis – Pipeline by Grupo Ferrer Internacional SA, 278
Atopic Dermatitis – Pipeline by Han Wha Pharma Co Ltd, 279
Atopic Dermatitis – Pipeline by HanAll Biopharma Co Ltd, 280
Atopic Dermatitis – Pipeline by Heptares Therapeutics Ltd, 281
Atopic Dermatitis – Pipeline by Herantis Pharma Plc, 282
Atopic Dermatitis – Pipeline by iCo Therapeutics Inc., 283
Atopic Dermatitis – Pipeline by Immune Pharmaceuticals Inc, 284
Atopic Dermatitis – Pipeline by Inflamalps SA, 285
Atopic Dermatitis – Pipeline by Japan Tobacco Inc, 286
Atopic Dermatitis – Pipeline by Johnson & Johnson, 287
Atopic Dermatitis – Pipeline by Kang Stem Biotech Co Ltd, 288
Atopic Dermatitis – Pipeline by KPI Therapeutics Inc, 289
Atopic Dermatitis – Pipeline by LEO Pharma A/S, 290
Atopic Dermatitis – Pipeline by Madam Therapeutics BV, 291
Atopic Dermatitis – Pipeline by MedImmune LLC, 292
Atopic Dermatitis – Pipeline by Mitsubishi Tanabe Pharma Corp, 293
Atopic Dermatitis – Pipeline by NeoPharm Co Ltd, 294
Atopic Dermatitis – Pipeline by Novan Inc, 295
Atopic Dermatitis – Pipeline by Novartis AG, 296
Atopic Dermatitis – Pipeline by Orbis Biosciences Inc, 297
Atopic Dermatitis – Pipeline by Otsuka Holdings Co Ltd, 298
Atopic Dermatitis – Pipeline by Oxagen Ltd, 299
Atopic Dermatitis – Pipeline by Pfizer Inc, 300
Atopic Dermatitis – Pipeline by Pharis Biotec GmbH, 301
Atopic Dermatitis – Pipeline by Pharmedartis GmbH, 302
Atopic Dermatitis – Pipeline by Provectus Biopharmaceuticals Inc, 303
Atopic Dermatitis – Pipeline by PuriCore Plc, 304
Atopic Dermatitis – Pipeline by Regeneron Pharmaceuticals Inc, 305
Atopic Dermatitis – Pipeline by Roivant Sciences Ltd, 306
Atopic Dermatitis – Pipeline by Signum Dermalogix Inc, 307
Atopic Dermatitis – Pipeline by Spherium Biomed SL, 308
Atopic Dermatitis – Pipeline by sterna biologicals Gmbh & Co KG, 309
Atopic Dermatitis – Pipeline by Sucampo Pharmaceuticals Inc, 310
Atopic Dermatitis – Pipeline by Sun Pharma Advanced Research Company Ltd, 311
Atopic Dermatitis – Pipeline by SWITCH Biotech LLC, 312
Atopic Dermatitis – Pipeline by Takeda Pharmaceutical Company Ltd, 313
Atopic Dermatitis – Pipeline by Thesan Pharmaceuticals Inc, 314
Atopic Dermatitis – Pipeline by Torrent Pharmaceuticals Ltd, 315
Atopic Dermatitis – Pipeline by Trevi Therapeutics Inc, 316
Atopic Dermatitis – Pipeline by Valeant Pharmaceuticals International Inc, 317
Atopic Dermatitis – Pipeline by Vicore Pharma AB, 318
Atopic Dermatitis – Pipeline by Vitae Pharmaceuticals Inc, 319
Atopic Dermatitis – Pipeline by VivaCell Biotechnology Espana SL, 320
Atopic Dermatitis – Pipeline by Xencor Inc, 321
Atopic Dermatitis – Pipeline by Ziarco Pharma Ltd 322
Assessment by Monotherapy Products 323
Assessment by Combination Products 324
Number of Products by Stage and Target 326
Number of Products by Stage and Mechanism of Action 329
Number of Products by Stage and Route of Administration 332
Number of Products by Stage and Molecule Type 334
Assessment by Monotherapy Products 335
Assessment by Combination Products 336
Number of Products by Stage and Target 338
Number of Products by Stage and Mechanism of Action 348
Number of Products by Stage and Route of Administration 360
Number of Products by Stage and Molecule Type 362
Assessment by Monotherapy Products 363
Number of Products by Stage and Target 365
Number of Products by Stage and Mechanism of Action 369
Number of Products by Stage and Route of Administration 374
Number of Products by Stage and Molecule Type 376
Acne Vulgaris – Dormant Projects 377
Psoriasis – Dormant Projects 380
Atopic Dermatitis – Dormant Projects 389
Acne Vulgaris – Discontinued Products, 392
Psoriasis – Discontinued Products, 392
Atopic Dermatitis – Discontinued Products, 39

Number of Products under Development for Acne Vulgaris, 16
Number of Products under Development for Acne Vulgaris – Comparative Analysis, 17
Number of Products under Development for Psoriasis, 18
Number of Products under Development for Psoriasis – Comparative Analysis, 19
Number of Products under Development for Atopic Dermatitis, 20
Number of Products under Development for Atopic Dermatitis – Comparative Analysis, 21
Number of Products under Development by Companies, 22
Number of Products under Development by Companies, 24
Number of Products under Development by Companies, 31
Number of Products under Investigation by Universities/Institutes, 34
Number of Products under Investigation by Universities/Institutes, 35
Number of Products under Investigation by Universities/Institutes, 36
Comparative Analysis by Late Stage Development, 37
Comparative Analysis by Clinical Stage Development, 38
Comparative Analysis by Early Stage Products, 39
Comparative Analysis by Late Stage Development, 40
Comparative Analysis by Clinical Stage Development, 41
Comparative Analysis by Early Stage Products, 42
Comparative Analysis by Late Stage Development, 44
Comparative Analysis by Clinical Stage Development, 45
Comparative Analysis by Early Stage Products, 46
Assessment by Monotherapy Products 323
Assessment by Combination Products 324
Number of Products by Top 10 Targets 325
Number of Products by Stage and Top 10 Targets 325
Number of Products by Top 10 Mechanism of Actions 328
Number of Products by Stage and Top 10 Mechanism of Actions 328
Number of Products by Routes of Administration 331
Number of Products by Stage and Routes of Administration 331
Number of Products by Molecule Types 333
Number of Products by Stage and Molecule Types 333
Assessment by Monotherapy Products 335
Assessment by Combination Products 336
Number of Products by Top 10 Targets 337
Number of Products by Stage and Top 10 Targets 337
Number of Products by Top 10 Mechanism of Actions 347
Number of Products by Stage and Top 10 Mechanism of Actions 347
Number of Products by Top 10 Routes of Administration 359
Number of Products by Stage and Top 10 Routes of Administration 359
Number of Products by Top 10 Molecule Types 361
Number of Products by Stage and Top 10 Molecule Types 361
Assessment by Monotherapy Products 363
Number of Products by Top 10 Targets 364
Number of Products by Stage and Top 10 Targets 364
Number of Products by Top 10 Mechanism of Actions 368
Number of Products by Stage and Top 10 Mechanism of Actions, 368
Number of Products by Top 10 Routes of Administration 373
Number of Products by Stage and Top 10 Routes of Administration, 373
Number of Products by Top 10 Molecule Types 375
Number of Products by Stage and Top 10 Molecule Types 375

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +